HARBOURVEST-PARTNERS
HarbourVest Partners, a global, independent private markets asset manager with $76 billion in AUM, today announced the opening of its office in Frankfurt, Germany to address increased demand from institutional and private wealth clients for innovative and broad ranging investment solutions.
Frankfurt is the second international expansion for HarbourVest this year following the opening of its Singapore office in May. This grows the firm’s global footprint to 12 locations across EMEA, the Americas, and Asia Pacific. The office is fully integrated into the firm’s global network, providing clients with seamless access to private equity, private credit, real assets and infrastructure investments.
HarbourVest has been active in the German market for over 30 years, investing in the country and managing significant capital for investors such as pension funds, insurance companies, and family offices through fund and separately managed account solutions.
“We are pleased to announce the expansion of our European office network with the opening of our office in Frankfurt,” said Peter Wilson, Managing Director. “The German market is one of the strongest and most influential in Europe with institutional, private client, and wealth management channels continuously increasing their allocation to private markets and seeking innovative solutions from investment managers. This is an exciting stage in our evolution as we continue to grow our capabilities across EMEA and further deepen our connections with German clients.”
The Frankfurt team will be led by HarbourVest Managing Director Olav König, alongside newly appointed Principal Martina Schliemann, who brings 23 years of local market experience working with German managers and investors. The team will offer clients access to a broad range of expertise across investments, investor relations and operations.
The Frankfurt office will operate as HarbourVest Partners (Ireland) Limited, Zweigniederlassung Deutschland. HarbourVest Partners (Ireland) Limited, Zweigniederlassung Deutschland is authorized by the Central Bank of Ireland as a branch of HarbourVest Partners (Ireland) Limited, an Alternative Investment Fund Manager authorized to conduct certain regulated activities within the EU. HarbourVest’s operations in Germany will be supervised by the Board of Directors of HarbourVest Partners (Ireland) Limited.
The firm has also become a proud member of the Bundesverband Alternative Investments e.V. (BAI), the industry body for alternative investments in Germany.
For more information about HarbourVest, please visit https://www.harbourvest.com/ .
ABOUT HARBOURVEST
HarbourVest is an independent, global private markets investment specialist with over 35 years of experience and more than $76 billion in assets under management, as of March 31, 2021. The Firm’s powerful global platform offers clients investment opportunities in private equity, private credit and real assets and infrastructure through primary fund investments, secondary investments, and direct co-investments, in commingled funds or separately managed accounts. HarbourVest has more than 700 employees, including more than 150 investment professionals across Asia, Europe, and the Americas. This global team has committed more than $46 billion to newly-formed funds, completed over $29 billion in secondary purchases, and invested over $21 billion directly in operating companies. Partnering with HarbourVest, clients have access to customized solutions, longstanding relationships, and actionable insights.
Nothing herein should be construed as a solicitation, offer, recommendation, representation of suitability, legal advice, tax advice, or endorsement of any security or investment and should not be relied upon by you in evaluating the merits of investing in HarbourVest funds or in any other investment decision. Information about the fund is not representative of any other HarbourVest fund or investment product.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005191/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DBS and Ant International Enhance Strategic Partnership to Scale Innovative Cross-Border Payment and Fintech Solutions to Drive Inclusive Growth13.11.2025 04:00:00 CET | Press release
MoU signed at the Singapore Fintech Festival 2025 covers several areas of strategic cooperation to scale digital payments, strengthen connectivity and advance fintech innovationPartnership enables DBS PayLah! users to scan Alipay+ QR codes to pay at more than 150 million merchants across over 100 markets DBS and Ant International have agreed to deepen their existing strategic collaboration to jointly explore innovative payments, digitisation and fintech solutions aimed at providing more inclusive services for regional businesses of all sizes and individual consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112714266/en/ From left to right: Tan Su Shan, CEO of DBS, Loy Hwee Chuan, Segment Head of Telecommunications, Media & Tech, Hong Kong and GBA, DBS, Edward Yue, Alipay+ General Manager for SEA, ANZ and South Asia at Ant International, Peng Yang, CEO of Ant International The collaboration will leverage DBS’ digita
LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 202513.11.2025 01:00:00 CET | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE). Poster Presentation Details Title Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity Date and time Wednesday, December 10, 2025, 08:00 (GMT) Poster number 309P Location The Churchill Room, Queen Elizabeth II Centre, London Bispecific TCE Overview For the selected target, LabGenius has developed a selectivity-enhanced TCE. The compa
VeriSilicon and Google Jointly Launch Open-Source Coral NPU IP13.11.2025 01:00:00 CET | Press release
Targeting edge LLM applications, accelerating edge AI ecosystem development VeriSilicon (688521.SH) recently announced the joint launch of the Coral NPU IP with Google, targeting always-on, ultra-low-energy edge Large Language Model (LLM) applications. The IP is based on Google’s foundational research in open machine learning compilers and enhanced with AI security features, providing developers with a unified open-source platform to build a robust edge AI ecosystem. The Coral NPU is built on the open RISC-V instruction set architecture, featuring native tensor processing capabilities, supporting mainstream machine learning frameworks such as JAX, PyTorch, and TensorFlow Lite (TFLite), and utilizing open-standard tools like Multi-Level Intermediate Representation (MLIR) from the Low Level Virtual Machine (LLVM) project for compiler infrastructure. It is designed for always-on, ultra-low-energy edge AI applications, particularly for wearable devices and ambient sensing systems. The Cora
Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression13.11.2025 00:00:00 CET | Press release
Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our goal was to rethink how to study topical drugs in early phase studies. The results of this study demonstrate that microdosing for only 3 days can provide meaningful efficacy signals. Within just 24 hours, we observed alterations in gene expression after applying a microdose of mid-potency corticosteroid on the skin of patients. By 72 hours, Th2, Th22 and Th17-specific biomarkers were significantly reduced. This outcome is exactly what we hoped for and opens the door to faster, smarter drug development strategies, demonstrat
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem samarbejde med VaporVM12.11.2025 23:54:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for digital transformation og cybersikkerhed med tilføjelsen af samarbejdspartneren VaporVM, der er et cloud-native teknologifirma med hovedsæde i Dubai. VaporVM, der blev grundlagt i 2017, hjælper globale virksomheder med at navigere i digital transformation gennem integrerede cloud-tjenester, DevOps, cybersikkerhed, datavidenskab og modernisering af applikationer. Med fokus på skalerbarhed og hurtigere lanceringer arbejder firmaet med Fortune 500-virksomheder og udnytter deres ekspertise og automatisering til at effektivisere it-drift og fremskynde digitale resultater. "Hos VaporVM brænder vi for at hjælpe virksomheder med ikke bare at tage nye teknologier til sig, men også at gentænke, hvad der kan lade sig gøre, når de bruges til at skabe reel forandring," siger Aqeel Asim, der er CEO og grundlægger af VaporVM. "Samarbejdet med Andersen Consulting giver os mulighed for at løfte vores mission til et globalt niveau – så vi kan bringe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom